Using psilocybin therapy in end-of-life care: views from patients and providers

Forty-three percent of palliative care stakeholders reported good knowledge of psilocybin's potential benefits and risks.

• Attitudes toward psilocybin-assisted therapy were predominantly non-favorable, with 61% of stakeholders expressing negative views.
• Favorable attitudes varied significantly across occupational groups, with 95% of physicians reporting positive views.
• The lack of trained healthcare providers was identified as the primary barrier to implementing psilocybin-assisted therapy.
• Key facilitators for implementation included the need for further research and the development of standardized intervention protocols.
• Sixty-eight percent of stakeholders supported introducing psilocybin-assisted therapy during the early stages of illness.

Simplified